Published in Br J Ophthalmol on July 01, 1978
Accuracy of pupil assessment for the detection of glaucoma: a systematic review and meta-analysis. Ophthalmology (2013) 0.92
Pupil cycle time: a simple way of measuring an autonomic reflex. J Neurol Neurosurg Psychiatry (1986) 0.88
The Pulfrich phenomenon and its alleviation with a neutral density filter. Br J Ophthalmol (1989) 0.84
Ocular complications in newly diagnosed borderline lepromatous and lepromatous leprosy patients: baseline profile of the Indian cohort. Br J Ophthalmol (2002) 0.83
Tonic and phasic co-variation of peripheral arousal indices in infants. Biol Psychol (2015) 0.75
Pupil cycle time and contrast sensitivity in type II diabetes mellitus patients: a pilot study. Indian J Ophthalmol (2011) 0.75
Pupil cycle time and early autonomic involvement in ocular leprosy. Br J Ophthalmol (1991) 0.75
The pupil cycle time test: age variations in normal subjects. Br J Ophthalmol (1981) 0.75
A SIMPLE METHOD FOR THE EARLY DIAGNOSIS OF ABNORMALITIES OF THE PUPILLARY REACTION. Br J Ophthalmol (1944) 2.26
The pupillogram and narcolepsy. A method to measure decreased levels of wakefulness. Neurology (1969) 1.53
Induced Pupillary Oscillations. Br J Ophthalmol (1950) 1.27
Pupil size and spontaneous pupillary waves associated with alertness, drowsiness, and sleep. Neurology (1970) 1.13
The ocular manifestations of disseminated sclerosis. Proc R Soc Med (1952) 1.05
Hippus and other spontaneous rhythmic pupillary waves. Am J Ophthalmol (1970) 0.89
Disintegration of central autonomic regulation during fatigue and its reintegration by psychosensory controlling mechanisms. II. Disintegration; pupillographic studies. J Nerv Ment Dis (1952) 0.86
Hippus. Semantic and historic considerations of the word. Am J Ophthalmol (1971) 0.85
Hippus. Arch Intern Med (1969) 0.85
A simple, inexpensive electronic pupillometer. Vision Res (1965) 0.85
Testing a servoanalytic hypothesis for pupil oscillations. Science (1958) 0.85
Visual loss in pseudotumor cerebri. Follow-up of 57 patients from five to 41 years and a profile of 14 patients with permanent severe visual loss. Arch Neurol (1982) 3.50
Active suppression of 1-fluoro-2,4-dinitrobenzene-immune T cells. Requirement of an auxiliary T cell induced by antigen. J Exp Med (1979) 3.35
CTLA-4: a negative regulator of autoimmune disease. J Exp Med (1996) 3.25
Functional evidence for epitope spreading in the relapsing pathology of experimental autoimmune encephalomyelitis. J Exp Med (1995) 2.62
An important role for the chemokine macrophage inflammatory protein-1 alpha in the pathogenesis of the T cell-mediated autoimmune disease, experimental autoimmune encephalomyelitis. J Immunol (1995) 2.52
Inhibition of specific immune responses by feeding protein antigens. IV. Evidence for tolerance and specific active suppression of cell-mediated immune responses to ovalbumin. J Immunol (1979) 2.29
The induction of cell-mediated immunity and tolerance with protein antigens coupled to syngeneic lymphoid cells. J Exp Med (1979) 2.09
Theiler's murine encephalomyelitis virus (TMEV)-induced demyelinating disease in mice is influenced by the H-2D region: correlation with TEMV-specific delayed-type hypersensitivity. J Immunol (1985) 2.06
Adrenergic mydriasis in Horner's syndrome. Hydroxyamphetamine test for diagnosis of postganglionic defects. Am J Ophthalmol (1971) 2.04
Monocytes/macrophages isolated from the mouse central nervous system contain infectious Theiler's murine encephalomyelitis virus (TMEV). Virology (1990) 1.90
Immune suppression with supraoptimal doses of antigen in contact sensitivity. I. Demonstration of suppressor cells and their sensitivity to cyclophosphamide. J Immunol (1977) 1.87
A splenic requirement for the generation of suppressor T cells. J Immunol (1977) 1.86
Adie's syndrome: some new observations. Trans Am Ophthalmol Soc (1977) 1.81
Pathologic role and temporal appearance of newly emerging autoepitopes in relapsing experimental autoimmune encephalomyelitis. J Immunol (2000) 1.76
Characterization of Theiler's murine encephalomyelitis virus (TMEV)-specific delayed-type hypersensitivity responses in TMEV-induced demyelinating disease: correlation with clinical signs. J Immunol (1986) 1.76
Suppressive mechanisms involving sensitization and tolerance in contact allergy. Immunol Rev (1980) 1.72
Development of spontaneous autoimmune peripheral polyneuropathy in B7-2-deficient NOD mice. J Exp Med (2001) 1.70
The induction of hapten-specific T cell tolerance by using hapten-modified lymphoid cells. I. Characteristics of tolerance induction. J Immunol (1976) 1.68
Astrocytes in multiple sclerosis: a product of their environment. Cell Mol Life Sci (2008) 1.66
The induction of hapten-specific T cell tolerance using hapten-modified lymphoid membranes. II. Relative roles of suppressor T cells and clone inhibition in the tolerant state. Eur J Immunol (1977) 1.66
Critical evaluation of the cocaine test in the diagnosis of Horner's syndrome. Arch Ophthalmol (1990) 1.63
The tonic pupil: a re-evaluation. Am J Ophthalmol (1967) 1.62
Antioxidants: what role do they play in physical activity and health? Am J Clin Nutr (2000) 1.60
Differential expression of inflammatory cytokines parallels progression of central nervous system pathology in two clinically distinct models of multiple sclerosis. J Immunol (1998) 1.59
Fuchs's heterochromic cyclitis: A critical review of the literature. I. Clinical characteristics of the syndrome. Surv Ophthalmol (1974) 1.57
Structured interview data on 102 cases of multiple personality disorder from four centers. Am J Psychiatry (1990) 1.56
Interferon gamma induction during oral tolerance reduces T-cell migration to sites of inflammation. Gastroenterology (2000) 1.55
Community-acquired pneumonia due to penicillin-resistant pneumococci. N Engl J Med (1985) 1.54
Control of experimental contact sensitivity. Adv Immunol (1980) 1.54
Class I-deficient resistant mice intracerebrally inoculated with Theiler's virus show an increased T cell response to viral antigens and susceptibility to demyelination. Eur J Immunol (1993) 1.53
X-linked progressive cone dystrophy. Clinical characteristics of affected males and female carriers. Ophthalmology (1989) 1.49
Gastric administration of type II collagen delays the onset and severity of collagen-induced arthritis in rats. Clin Exp Immunol (1986) 1.49
The role of infections in autoimmune disease. Clin Exp Immunol (2009) 1.47
Congenital Horner's syndrome. Arch Ophthalmol (1980) 1.43
The functional significance of epitope spreading and its regulation by co-stimulatory molecules. Immunol Rev (1998) 1.43
First-in-human study of the safety and efficacy of TOL101 induction to prevent kidney transplant rejection. Am J Transplant (2014) 1.41
The diagnosis and prognosis of atypical carotid-cavernous fistula (red-eyed shunt syndrome). Am J Ophthalmol (1982) 1.41
Induction of active and adoptive relapsing experimental autoimmune encephalomyelitis (EAE) using an encephalitogenic epitope of proteolipid protein. J Neuroimmunol (1992) 1.41
Pupillary signs in the diagnosis of optic nerve disease. Trans Ophthalmol Soc U K (1976) 1.40
A critical role for B7/CD28 costimulation in experimental autoimmune encephalomyelitis: a comparative study using costimulatory molecule-deficient mice and monoclonal antibody blockade. J Immunol (2000) 1.40
Hydroxyamphetamine mydriasis in Horner's syndrome. Am J Ophthalmol (1990) 1.39
An anisocoria produces a small relative afferent pupillary defect in the eye with the smaller pupil. J Neuroophthalmol (1999) 1.38
The 5' noncoding sequences from a less virulent Theiler's virus dramatically attenuate GDVII neurovirulence. J Virol (1991) 1.37
Correlation of lymphocyte transformation with tuberculin skin-test sensitivity. Am Rev Respir Dis (1973) 1.36
How to measure the relative afferent pupillary defect. Surv Ophthalmol (1981) 1.35
Accuracy of clinical diagnosis of genital ulcer disease. Sex Transm Dis (1991) 1.35
Inhibition of murine relapsing experimental autoimmune encephalomyelitis by immune tolerance to proteolipid protein and its encephalitogenic peptides. J Immunol (1990) 1.34
Epitope spreading. Curr Opin Immunol (1996) 1.34
Direct activation of innate and antigen-presenting functions of microglia following infection with Theiler's virus. J Virol (2001) 1.34
Discordant effects of anti-VLA-4 treatment before and after onset of relapsing experimental autoimmune encephalomyelitis. J Clin Invest (2001) 1.32
The relationship between visual acuity, pupillary defect, and visual field loss. Am J Ophthalmol (1982) 1.32
Epitope spreading: lessons from autoimmune skin diseases. J Invest Dermatol (1998) 1.31
Neuroantigen-specific Th2 cells are inefficient suppressors of experimental autoimmune encephalomyelitis induced by effector Th1 cells. J Immunol (1995) 1.31
Suppressor T cell mechanisms in contact sensitivity. I. Efferent blockade by syninduced suppressor T cells. J Immunol (1978) 1.31
A virus-induced molecular mimicry model of multiple sclerosis. J Clin Invest (2001) 1.31
Pupillary "dilatation lag" in Horner's syndrome. Br J Ophthalmol (1975) 1.29
Raeder's syndrome. A clinical review. Surv Ophthalmol (1980) 1.29
Afferent pupillary defects. Pupillary findings associated with defects of the afferent arm of the pupillary light reflex arc. Am J Ophthalmol (1966) 1.24
Split tolerance of Th1 and Th2 cells in tolerance to Theiler's murine encephalomyelitis virus. Eur J Immunol (1993) 1.24
Class II-restricted T cell responses in Theiler's murine encephalomyelitis virus (TMEV)-induced demyelinating disease. II. Survey of host immune responses and central nervous system virus titers in inbred mouse strains. Microb Pathog (1987) 1.24
Endogenous presentation of self myelin epitopes by CNS-resident APCs in Theiler's virus-infected mice. J Clin Invest (1999) 1.23
Temporal development of autoreactive Th1 responses and endogenous presentation of self myelin epitopes by central nervous system-resident APCs in Theiler's virus-infected mice. J Immunol (2000) 1.22
Mechanisms of immunotherapeutic intervention by anti-CD40L (CD154) antibody in an animal model of multiple sclerosis. J Clin Invest (1999) 1.22
The effect of target behavior monitoring on weight loss and completion rate in a behavior modification program for weight reduction. Addict Behav (1986) 1.22
A novel technique for management of the en bloc bladder cuff and distal ureter during laparoscopic nephroureterectomy. J Urol (1999) 1.20
H-2 restriction of suppressor T-cell induction by hapten-modified lymphoid cells in tolerance to 1-fluoro-2,4-dinitrobenzene contact sensitization. J Exp Med (1977) 1.20
Clostridium difficile colitis associated with the use of antineoplastic agents. Eur J Clin Microbiol (1984) 1.20
Tolerance: two pathways of negative immunoregulation in contact sensitivity to DNFB. Cold Spring Harb Symp Quant Biol (1977) 1.19
Ectopia of the vas deferens. Pediatr Radiol (1995) 1.17
The rational management of idiopathic intracranial hypertension. Arch Neurol (1989) 1.17
Holmes-Adie syndrome with segmental hypohidrosis. Neurology (1967) 1.17
Requirements for induction of T cell tolerance to DNFB: efficiency of membrane-associated DNFB. J Immunol (1976) 1.16
Divergent roles for p55 and p75 tumor necrosis factor receptors in the pathogenesis of MOG(35-55)-induced experimental autoimmune encephalomyelitis. Cell Immunol (2000) 1.16
In vivo effects of GK1.5 (anti-L3T4a) monoclonal antibody on induction and expression of delayed-type hypersensitivity. Cell Immunol (1985) 1.15
Risk of infection after open fracture of the arm or leg. Arch Surg (1988) 1.14
Posterior transvertebral osteotomy for adult thoracolumbar kyphosis. Spine (Phila Pa 1976) (1994) 1.11
Treatment with bacterial LPS renders genetically resistant C57BL/6 mice susceptible to Theiler's virus-induced demyelinating disease. J Immunol (1995) 1.11
Alterations of murine immunologic responses after silica dust inhalation. J Immunol (1974) 1.11
Elevated levels of serum immunoglobulins in asymptomatic carriers of Clostridium difficile. Clin Infect Dis (1993) 1.11
Automated pupil perimetry. Pupil field mapping in patients and normal subjects. Ophthalmology (1991) 1.10
Flow cytometric and functional analyses of central nervous system-infiltrating cells in SJL/J mice with Theiler's virus-induced demyelinating disease. Evidence for a CD4+ T cell-mediated pathology. J Immunol (1996) 1.10
Two models of multiple sclerosis: experimental allergic encephalomyelitis (EAE) and Theiler's murine encephalomyelitis virus (TMEV) infection. A pathological and immunological comparison. Microsc Res Tech (1995) 1.10
Virus-induced autoimmunity: potential role of viruses in initiation, perpetuation, and progression of T-cell-mediated autoimmune disease. Viral Immunol (2001) 1.10
CD8-deficient SJL mice display enhanced susceptibility to Theiler's virus infection and increased demyelinating pathology. J Neurovirol (2001) 1.10
Psychosocial mediators of racial differences in nighttime blood pressure dipping among normotensive adults. Health Psychol (1999) 1.09
Diagnosing Horner's syndrome. Trans Sect Ophthalmol Am Acad Ophthalmol Otolaryngol (1978) 1.09
Inhibition of Theiler's virus-mediated demyelination by peripheral immune tolerance induction. J Immunol (1995) 1.09
Regulation of the effector stages of experimental autoimmune encephalomyelitis via neuroantigen-specific tolerance induction. II. Fine specificity of effector T cell inhibition. J Immunol (1992) 1.08
Absence of growth retardation in children with perennial allergic rhinitis after one year of treatment with mometasone furoate aqueous nasal spray. Pediatrics (2000) 1.08
Cerebral phaeohyphomycosis caused by Xylohypha bantiana. Eur J Clin Microbiol Infect Dis (1989) 1.07
IFN-gamma-activated primary murine astrocytes express B7 costimulatory molecules and prime naive antigen-specific T cells. J Immunol (1997) 1.07
Functional visual loss. Follow-up of 42 cases. Arch Ophthalmol (1983) 1.07
Specific immune regulation of chronic-relapsing experimental allergic encephalomyelitis in mice. J Immunol (1988) 1.06
Hydroxyamphetamine mydriasis in normal subjects. Am J Ophthalmol (1990) 1.05
Prevention of pristane-induced arthritis by the oral administration of type II collagen. Immunology (1993) 1.05
Regulation of the effector stages of experimental autoimmune encephalomyelitis via neuroantigen-specific tolerance induction. J Immunol (1990) 1.04